tbuckley/cabot-search huggingface dataset:
ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome
Authors: Erin M. Parry, Camilla K. Lemvigh, Stephanie Deng, Nathan Dangle, Neil Ruthen, Binyamin A. Knisbacher, Julien Broséus, Sébastien Hergalant, Romain Guièze, Shuqiang Li, Wandi Zhang, Connor Johnson, Jaclyn M. Long, Shanye Yin, Lillian Werner, Annabelle Anandappa, Noelia Purroy, Satyen Gohil, Giacomo Oliveira, Pavan Bachireddy, Sachet A. Shukla, Teddy Huang, Joseph D. Khoury, Beenu Thakral, Michael Dickinson, Constantine Tam, Kenneth J. Livak, Gad Getz, Donna Neuberg, Pierre Feugier, Peter Kharchenko, William Wierda, Lars Rønn Olsen, Nitin Jain, Catherine J. Wu
Journal: Cancer Cell (2023)
Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach
Authors: Dhivya Sridaran, Elliot Bradshaw, Carl DeSelm, Russell Pachynski, Kiran Mahajan, Nupam P. Mahajan
Journal: Cell Reports Medicine (2023)

Cancer immunotherapy has gained traction in recent years owing to remarkable tumor clearance in some patients. Despite the notable success of immune checkpoint blockade (ICB) in multiple malignancies, engagement of the immune system for targeted prostate cancer (PCa) therapy is still in its infancy. Multiple factors contribute to limited response, including the heterogeneity of PCa, the cold tumor microenvironment, and a low number of neoantigens. Significant effort is being invested in improving immune-based PCa therapies. This review is a summary of the status of immunotherapy in treating PCa, with a discussion of multiple immune modalities, including vaccines, adoptively transferred T cells, and bispecific T cell engagers, some of which are undergoing clinical trials. In addition, this review also focuses on emerging mechanism-based small-molecule tyrosine kinase inhibitors with immune modulatory properties that, either as single agents or in combination with other immunotherapies, have the potential to improve clinical outcomes.
A single-cell atlas of CD19 chimeric antigen receptor T cells
Authors: Xubin Li, Jared Henderson, Max J. Gordon, Irtiza Sheikh, Loretta J. Nastoupil, Jason Westin, Christopher Flowers, Sairah Ahmed, Linghua Wang, Sattva S. Neelapu, Paolo Strati, Qing Deng, Michael R. Green
Journal: Cancer Cell (2023)
Cardiopulmonary response to exercise in adults born very preterm
Authors: Jacques Delfrate, Camille Girard-Bock, Daniel Curnier, Delphine Perie, Anik Cloutier, Gabrielle Gascon, Jennifer S. Landry, Benoît Masse, Michael K. Stickland, Anne Monique Nuyt, Thuy Mai Luu
Journal: European Respiratory Journal (2023)

This study aims to compare cardiopulmonary response to aerobic exercise between young adults born very preterm, including a subgroup with bronchopulmonary dysplasia (BPD), and term controls. Seventy-one adults (18–29 years) born &lt;30 weeks’ gestational age (24 with BPD) and 73 term controls were recruited. Assessment included cardiopulmonary exercise testing with impedance cardiography. We compared group differences in peak O 2 consumption (peak VO 2 ) and in ventilatory and cardiovascular responses to exercise using linear regression analyses. Preterm participants had reduced peak VO 2 (mean difference −2.7; 95% CI −5.3, −0.1 mL·kg −1 lean body mass·min −1 ) versus controls. Those with BPD achieved lower peak work-rate compared to term controls (−21; 95% CI −38, −5 watts). There was no difference across groups in breathing reserve, ventilatory efficiency, peak heart rate and cardiac output. VO 2 to work-rate relationship (ΔVO 2 /ΔWR) was reduced in preterm versus term. Peak systolic blood pressure and circulatory power (systolic blood pressure*VO 2 ) were also lower in BPD versus term controls. In the preterm group, longer NICU stay and lower peak cardiac output were associated with lower peak VO 2 . Results suggest limitations with peripheral O 2 uptake in the muscle with reduced ΔVO 2 /ΔWR and peak circulatory power, but normal cardiac output. Investigations into skeletal muscle perfusion and O 2 use during exercise are warranted to better understand mechanisms of exercise limitation.
Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
Authors: Alessandro G. Fiocchi, Wanda Phipatanakul, Robert S. Zeiger, Sandy R. Durrani, Jeremy Cole, Jérôme Msihid, Rebecca Gall, Juby A. Jacob-Nara, Yamo Deniz, Paul J. Rowe, David J. Lederer, Megan Hardin, Yi Zhang, Asif H. Khan
Journal: European Respiratory Journal (2023)

Dupilumab has shown long-term treatment benefits in children with uncontrolled asthma. We assessed in more detail the impact of dupilumab on asthma control and health-related quality of life (HRQoL) in children and their caregivers.Children aged 6-11 years with uncontrolled moderate-to-severe type 2 asthma (baseline blood eosinophils ≥150 cells·µL-1 or fractional exhaled nitric oxide ≥20 ppb; n=350) were treated with dupilumab or placebo for 52 weeks in the VOYAGE study. Primary outcomes of these analyses were asthma control (change from baseline in Asthma Control Questionnaire 7 Interviewer-Administered (ACQ-7-IA) and achieving a clinically meaningful response of ≥0.5 points); proportion of patients achieving well-controlled asthma or better (ACQ-7-IA ≤0.75 points); effect on patients' (Standardised Paediatric Asthma Quality of Life Questionnaire Interviewer-Administered (PAQLQ(S)-IA)) and caregivers' (Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ)) HRQoL; and allergic rhinitis-related QoL.Dupilumab versus placebo significantly improved children's ACQ-7-IA scores by week 4 with sustained improvements through week 52 (least squares mean difference at week 52: -0.44, 95% CI -0.59- -0.30; p<0.0001); a higher proportion achieved a clinically meaningful response (week 52: 86% versus 75%; p=0.0051). At weeks 24 and 52, more children who received dupilumab achieved well-controlled asthma (ACQ-7-IA ≤0.75 points: 61% versus 43%; p=0.0001 and 70% versus 46%; p<0.0001, respectively). Significant improvements in PAQLQ(S)-IA and PACQLQ scores were observed by week 52.In children aged 6-11 years with moderate-to-severe type 2 asthma, dupilumab treatment was associated with rapid, sustained improvements in asthma control. HRQoL was significantly improved for children and their caregivers.
Hypoxic burden to guide CPAP treatment allocation in patients with obstructive sleep apnoea: a<i>post hoc</i>study of the ISAACC trial
Authors: Lucía Pinilla, Neda Esmaeili, Gonzalo Labarca, Miguel Ángel Martinez-Garcia, Gerard Torres, Esther Gracia-Lavedan, Olga Mínguez, Dolores Martínez, Jorge Abad, Maria José Masdeu, Olga Mediano, Carmen Muñoz, Valentín Cabriada, Joaquín Duran-Cantolla, Mercè Mayos, Ramón Coloma, Josep María Montserrat, Mónica de la Peña, Wen-Hsin Hu, Ludovico Messineo, Mohammadreza Sehhati, Andrew Wellman, Susan Redline, Scott Sands, Ferran Barbé, Manuel Sánchez-de-la-Torre, Ali Azarbarzin
Journal: European Respiratory Journal (2023)

Background Hypoxic burden (HB) has emerged as a strong predictor of cardiovascular risk in obstructive sleep apnoea (OSA). We aimed to assess the potential of HB to predict the cardiovascular benefit of treating OSA with continuous positive airway pressure (CPAP). Methods This was a post hoc analysis of the ISAACC trial ( ClinicalTrials.gov : NCT01335087 ) including non-sleepy patients with acute coronary syndrome (ACS) diagnosed with OSA (apnoea–hypopnoea index ≥15 events·h −1 ) by respiratory polygraphy. Patients were randomised to CPAP or usual care and followed for a minimum of 1 year. HB was calculated as the total area under all automatically identified desaturations divided by total sleep time. Patients were categorised as having high or low baseline HB according to the median value (73.1%min·h −1 ). Multivariable Cox regression models were used to assess whether the effect of CPAP on the incidence of cardiovascular outcomes was dependent on the baseline HB level. Results The population (362 patients assigned to CPAP and 365 patients assigned to usual care) was middle-aged (mean age 59.7 years), overweight/obese and mostly male (84.5%). A significant interaction was found between the treatment arm and the HB categories. In the high HB group, CPAP treatment was associated with a significant reduction in the incidence of cardiovascular events (HR 0.57, 95% CI 0.34–0.96). In the low HB group, CPAP-treated patients exhibited a trend toward a higher risk of cardiovascular outcomes than those receiving usual care (HR 1.33, 95% CI 0.79–2.25). The differential effect of the treatment depending on the baseline HB level followed a dose–response relationship. Conclusion In non-sleepy ACS patients with OSA, high HB levels were associated with a long-term protective effect of CPAP on cardiovascular prognosis.
Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I
Authors: Valentina Ferrari, Antonino Lo Cascio, Alessia Melacarne, Nina Tanasković, Alessandro M. Mozzarelli, Luca Tiraboschi, Michela Lizier, Marta Salvi, Daniele Braga, Francesca Algieri, Giuseppe Penna, Maria Rescigno
Journal: Cancer Cell (2023)
<i>Notes from the Field</i>: Circulating Vaccine-Derived Poliovirus Type 2 Emergences Linked to Novel Oral Poliovirus Vaccine Type 2 Use — Six African Countries, 2021–2023
Authors: Elizabeth Davlantes, Jaume Jorba, Elizabeth Henderson, Kelley Bullard, Mark. A. Deka, Anfumbom Kfutwah, Javier Martin, Maël Bessaud, Lester M. Shulman, Kaija Hawes, Ousmane M. Diop, Ananda S. Bandyopadhyay, Simona Zipursky, Cara C. Burns
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Progress Toward Poliomyelitis Eradication — Afghanistan, January 2022–June 2023
Authors: Adam Bjork, Irfan Elahi Akbar, Sumangala Chaudhury, Mufti Zubair Wadood, Fazal Ather, Jaume Jorba, Maureen Martinez
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

When the Global Polio Eradication Initiative began in 1988, wild poliovirus (WPV) transmission was reported in 125 countries. Since 2017, Afghanistan and Pakistan remain the only countries with uninterrupted endemic WPV type 1 (WPV1) transmission. This report describes activities and progress toward polio eradication in Afghanistan during January 2022-June 2023. Two WPV1 cases were reported during January-December 2022 and five during January-June 2023 (as of August 26), all from three provinces in the southeast and east regions bordering Pakistan. All five 2023 patients had reportedly received ≥16 oral poliovirus vaccine doses. WPV1 was detected in sewage samples from a site in the south region in May 2023 and one in the north region in June 2023, the first detections since February 2021 and March 2020, respectively. Restrictions on house-to-house vaccination limit the effectiveness of vaccination campaigns in parts of the south and northeast regions. Because of population movement, the risk for transmission in Afghanistan and Pakistan will remain if WPV1 circulation continues in either country. Despite operational improvements in vaccination activities, interruption of WPV1 transmission in Afghanistan will require committed, uninterrupted efforts, including ongoing coordination with Pakistan on polio eradication activities, to address vaccination coverage gaps that sustain WPV1 circulation.
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity
Authors: Talha Badar, Yenny A Moreno Vanegas, Ahmad Nanaa, James M Foran, Aref Al-Kali, Abhishek Mangaonkar, Hemant Murthy, Hassan B Alkhateeb, David Viswanatha, Rong He, Mithun Shah, Cecilia Arana Yi, Mark R Litzow, Naseema Gangat, Ayalew Tefferi, Mrinal M Patnaik
Journal: Blood Cancer Journal (2023)

Abstract We have previously recognized the genotypic and prognostic heterogeneity of U2AF1 mutations (MT) in myelofibrosis (MF) and myelodysplastic syndromes (MDS). In the current study, we considered 179 U2AF1 -mutated patients with clonal cytopenia of undetermined significance (CCUS; n = 22), MDS ( n = 108), MDS/acute myeloid leukemia (AML; n = 18) and AML ( n = 31). U2AF1 variants included S34 (60%), Q157 (35%), and others (5%): corresponding mutational frequencies were 45%, 55%, and 0% in CCUS; 57%, 39%, and 4% in MDS; 61%, 33%, and 6% in MDS/AML; and 55%, 35% and 10% in AML ( P = 0.17, 0.36 and 0.09), respectively. Concurrent mutations included ASXL1 (37%), BCOR (19%), RUNX1 (14%), TET2 (15%), DNMT3A (10%), NRAS / KRAS (8%), TP53 (8%), JAK2 (5.5%) and SETBP1 (5%). The two most frequent U2AF1 MT were S34F ( n = 97) and Q157P ( n = 46); concurrent MT were more likely to be seen with the latter (91% vs 74%; P = 0.01) and abnormal karyotype with the former (70% vs 62%; P = 0.05). U2AF1 S34F MT clustered with BCOR ( P = 0.04) and Q157P MT with ASXL1 ( P = 0.01) and TP53 ( P = 0.03). The median overall survival (OS) in months was significantly worse in AML (14.2) vs MDS/AML (27.3) vs MDS (33.7; P = 0.001); the latter had similar OS with CCUS (30.0). In morphologically high-risk disease ( n = 49), defined by ≥10% blood or bone marrow blasts (i.e., AML or MDS/AML), median OS was 14.2 with Q157P vs 37.1 months in the presence of S34F ( P = 0.008); transplant-adjusted multivariable analysis confirmed the detrimental impact of Q157P ( P = 0.01) on survival and also identified JAK2 MT as an additional risk factor ( P = 0.02). OS was favorably affected by allogeneic hematopoietic stem cell transplantation (HR: 0.16, 95% CI; 0.04-0.61, P = 0.007). The current study defines the prevalence and co-mutational profiles of U2AF1 pathogenic variants in AML, MDS/AML, MDS, and CCUS, and suggests prognostic heterogeneity in patients with ≥10% blasts.
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
Authors: Danielle Hammond, Sanam Loghavi, Sa A. Wang, Marina Y. Konopleva, Tapan M. Kadia, Naval G. Daver, Maro Ohanian, Ghayas C. Issa, Yesid Alvarado, Nicholas J. Short, Koji Sasaki, Naveen Pemmaraju, Guillermo Montalban-Bravo, Curtis A. Lachowiez, Abhishek Maiti, Guillermo Garcia-Manero, Elias J. Jabbour, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Sherry R. Pierce, Hagop M. Kantarjian, Courtney D. DiNardo
Journal: Blood Cancer Journal (2023)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML
Seasonal Trends in Emergency Department Visits for Mental and Behavioral Health Conditions Among Children and Adolescents Aged 5–17 Years — United States, January 2018–June 2023
Authors: Lakshmi Radhakrishnan, Kelly Carey, Dylan Pell, Amy Ising, Danielle Brathwaite, Anna Waller, James Gay, Hollie Watson-Smith, Mark Person, Kenan Zamore, Tia Brumsted, Claudia Price, Patti M. Clark, Gabriel Ann Haas, Lauren Gracy, Scott Johnston, Yushiuan Chen, Kyla Muñoz, Meredith Henry, Brittany Willis, Darryl Nevels, Ibitola Asaolu, Sarah Lee, Natalie J. Wilkins, Sarah Bacon, Michael Sheppard, Aaron Kite-Powell, Gary Blau, Michael King, Meghan Whittaker, Rebecca T. Leeb
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

Mental and behavioral health conditions among school-aged children, including substance use disorders and overall emotional well-being, are a public health concern in the United States. Timely data on seasonal patterns in child and adolescent conditions can guide optimal timing of prevention and intervention strategies. CDC examined emergency department (ED) visit data from the National Syndromic Surveillance Program for 25 distinct conditions during January 2018-June 2023 among U.S. children and adolescents aged 5-17 years, stratified by age group. Each year, during 2018-2023, among persons aged 10-14 and 15-17 years, the number and proportion of weekly ED visits for eight conditions increased in the fall school semester and remained elevated throughout the spring semester; ED visits were up to twice as high during school semesters compared with the summer period. Among children aged 5-9 years, the number and proportion of visits increased for five mental and behavioral health conditions. Seasonal increases in ED visits for some conditions among school-aged children warrant enhanced awareness about mental distress symptoms and the challenges and stressors in the school environment. Systemic changes that prioritize protective factors (e.g., physical activity; nutrition; sleep; social, community, or faith-based support; and inclusive school and community environments) and incorporate preparedness for increases in conditions during back-to-school planning might improve child and adolescent mental health.
Thrombocytopenia Associated with Elemental Mercury Poisoning in Two Siblings — Connecticut, July 2022
Authors: Emily W. Hogeland, Tarah S. Somers, Luke Yip, Suzanne Doyon, Carrie A. Redlich, Andrea D. Orsey, Craig B. Woda, Suzannah T. Swan, Henry M. Feder
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

Two siblings aged 5 and 15 years from Connecticut were hospitalized with petechial rash, oral mucositis, and severe thrombocytopenia approximately 10 days after they played with a jar of elemental mercury they found in their home. Before the mercury exposure was disclosed, the siblings were treated with platelet transfusions, intravenous immune globulin (IVIG) for possible immune thrombocytopenic purpura, and antibiotics for possible infectious causes. When their conditions did not improve after 6 days, poison control facilitated further questioning about toxic exposures including mercury, testing for mercury, and chelation with dimercaptosuccinic acid. The older sibling soon recovered, but the younger child required a prolonged hospitalization for severe thrombocytopenia, ultimately receiving repeated doses of IVIG, steroids, and romiplostim, a thrombopoietin receptor agonist. Close collaboration among multiple agencies was required to identify the extent of mercury contamination, evaluate and treat the other family members, and decontaminate the home. These cases demonstrate the importance of ongoing public health outreach to promote early detection of elemental mercury toxicity, and the need to evaluate for environmental exposures when multiple close contacts experience similar signs and symptoms.
Joint statement in support of hepatitis C human challenge studies
Authors: Harvey J Alter, Eleanor Barnes, Mia J Biondi, Andrea L Cox, Jake D Eberts, Jordan J Feld, T Jake Liang, Josh Morrison, Charles M Rice, Naglaa H Shoukry, David L Thomas, Jennifer Van Gennip, Charles Weijer, Alessio Aghemo, Matthew Akiyama, Mohammad Ali, Harvey Alter, Ralf Bader, Justin R. Bailey, Yasemin Balaban, Sayantan Banerjee, Eleanor Barnes, Ralf Bartenschlager, Thomas F. Baumert, Marina Berenguer, Ajeet S. Bhadoria, Mia Biondi, Paolo Bonanni, Alcino E. Bonella, Philip Bruggmann, Julie Bruneau, Rowena A. Bull, Maia Butsashvili, Pedro Cahn, Arthur L. Caplan, Richard Y. Chappell, Francis Chisari, Ray Chung, Graham Cooke, Andrea L. Cox, Olav Dalgard, Doan Y. Dao, Ara Darzi, Douglas Dieterich, John F. Dillon, Gregory J. Dore, Joseph S. Doyle, Heidi E. Drummer, Anna P. Durbin, Geoffrey Dusheiko, Jake D. Eberts, Nir Eyal, Jordan Feld, Kyle Ferguson, Robert Flisiak, Xavier Forns, Graham R. Foster, Steven Foung, Meital Gal-Tanamy, Ed Gane, Adam J. Gehring, Jacob George, Marc G. Ghany, Daniel T. Gilbert, Kimberly Glaze, Kenneth W. Goodman, Jason Grebely, Saeed Hamid, Daniel M. Haybron, Richard Holton, Louis J. Ignarro, Tamika Jackson, Dale Jamieson, Jody Jollimore, Andrew Karaba, Marina Klein, Georg Lauer, Mansun Law, Stanley M. Lemon, T. Jake Liang, Lin Liu, Volker Lohmann, Lung-Yi Mak, Rui T. Marinho, Abigail A. Marsh, Lesley Miller, Joshua Morrison, Francesco Negro, Bao-Vuong Nguyen, Kimberly Page, Kerry Paterson, Alisa Pedrana, Thomas Pietschmann, Steven Pinker, Stanley Plotkin, Stuart C. Ray, Nancy Reau, William M. Remak, Charles M. Rice, Ezequiel Ridruejo, Richard J. Roberts, Alvin Roth, Nadine Rouphael, Rogier Sanders, Russell Sandvold, Arthur Schafer, Janke Schinkel, Wai-Kay Seto, Naglaa Shoukry, Peter Singer, Sunil Solomon, Chris Somerville, Mark W. Sonderup, Mark Sulkowski, Kawsar Talaat, Larry Temkin, Norah Terrault, Chloe Thio, David L. Thomas, Alexander J. Thompson, Netanel Tzarum, Marc van der Valk, Jennifer Van Gennip, Imam Waked, Alec Walen, Christopher M. Walker, Heiner Wedemeyer, Charles Weijer, Dan Wikler, Dominic Wilkinson, Heather Youngs, Man-fung Yuen, Barry Zack, Ekaterina Zinger
Journal: The Lancet. Gastroenterology & hepatology (2023)
Management of Hepatic Hydatid Disease - Current Surgical Practice
Authors: Suhail Khuroo, Ajaz Ahmed Wani, Farzana Feroze, Suhail Khuroo
Journal: International Journal of Surgery (2023)

Hydatid is a global disease and affects almost all organs of the body, liver being the most common. Patients with hydatid disease often present as a therapeutic challenge since there is no specific consensus regarding the optimal management. The complete therapy of hydatid disease should aim to eliminate the parasite to cure the disease. The first and important step should be prevention of the disease by implementation of safe hygienic practices. Medical and surgical management go hand in hand with surgery being the treatment of choice, controversy still exists about the most appropriate surgical approach. Surgical management remains the gold standard for liver hydatid cyst, however individualization of treatment modality depending upon the type, number, location, recurrent disease and complications is recommended.
Gut microbiota-derived short-chain fatty acids ameliorate methamphetamine-induced depression- and anxiety-like behaviors in a Sigmar-1 receptor-dependent manner
Authors: Kaikai Zhang, Lijian Chen, Jianzheng Yang, Jiali Liu, Jiahao Li, Yi Liu, Xiuwen Li, Long Chen, Clare Hsu, Jiahao Zeng, Xiaoli Xie, Qi Wang
Journal: Acta Pharmaceutica Sinica B (2023)

Methamphetamine (Meth) abuse can cause serious mental disorders, including anxiety and depression. The gut microbiota is a crucial contributor to maintaining host mental health. Here, we aim to investigate if microbiota participate in Meth-induced mental disorders, and the potential mechanisms involved. Here, 15 mg/kg Meth resulted in anxiety- and depression-like behaviors of mice successfully and suppressed the Sigma-1 receptor (SIGMAR1)/BDNF/TRKB pathway in the hippocampus. Meanwhile, Meth impaired gut homeostasis by arousing the Toll-like receptor 4 (TLR4)-related colonic inflammation, disturbing the gut microbiome and reducing the microbiota-derived short-chain fatty acids (SCFAs). Moreover, fecal microbiota from Meth-administrated mice mediated the colonic inflammation and reproduced anxiety- and depression-like behaviors in recipients. Further, SCFAs supplementation optimized Meth-induced microbial dysbiosis, ameliorated colonic inflammation, and repressed anxiety- and depression-like behaviors. Finally, Sigmar1 knockout (Sigmar1-/-) repressed the BDNF/TRKB pathway and produced similar behavioral phenotypes with Meth exposure, and eliminated the anti-anxiety and -depression effects of SCFAs. The activation of SIGMAR1 with fluvoxamine attenuated Meth-induced anxiety- and depression-like behaviors. Our findings indicated that gut microbiota-derived SCFAs could optimize gut homeostasis, and ameliorate Meth-induced mental disorders in a SIGMAR1-dependent manner. This study confirms the crucial role of microbiota in Meth-related mental disorders and provides a potential preemptive therapy.